gsrao2022
☆    

India,
2021-03-28 20:12
(299 d 03:12 ago)

Posting: # 22295
Views: 963
 

 BE study designing related doubts [Design Issues]

I have some doubts, could anyone help me out

  1. If any molecule intra subject CV of Cmax is less than 30 and for AUC more than 30. in this case can we go for replicate design for EU regulatory?

  2. For replicate study design which should be preferred partial replicate or full replicate? which is preferred by regulatory?

  3. What is the maximum half life to go for Parallel study?

  4. What is the minimum days of wash out period required (in days) for eg. if a molecule half-life is 1 hour?

  5. If a study passes 90 % CI, but the power is below 80 does regulatory approves the study?



Edit: Category changed; see also this post #1. Please follow the Forum’s Policy[Helmut]
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2021-03-29 00:41
(298 d 22:44 ago)

@ gsrao2022
Posting: # 22296
Views: 807
 

 BE study designing related doubts

Hi gsrao,

» 1. If any molecule intra subject CV of Cmax is less than 30 and for AUC more than 30. in this case can we go for replicate design for EU regulatory?

A replicate design is always accepted.

» 2. For replicate study design which should be preferred partial replicate or full replicate?

From a statistical perspective, a full replicate is preferred. When you are concerned about dropouts or the bioanalytical method requires large sample volumes, opt for one the 2-sequence 3-period designs (TRT|RTR or TRR|RTT).

» … which is preferred by regulatory?

Any one is fine. If you opt for a 2-sequence 3-period design (TRT|RTR or TTR|RRT) you need at least 12 eligible subjects in the sequence where R is repeated (see the Q&A document). However, that’s not relevant in practice, unless you face an extreme dropout-rate (see this post).

» 3. What is the maximum half life to go for Parallel study?

No fixed rules.

» 4. What is the minimum days of wash out period required (in days) for eg. if a molecule half-life is 1 hour?

In days? With 1/5 you are on the safe side. :-D
Never plan based on an average t½. The shortest washout I ever had were three days.

» 5. If a study passes 90 % CI, but the power is below 80 does regulatory approves the study?

Post hoc (a posteriori, retrospective) power is completely irrelevant (not only on BE) and there is no reason to reject a successful study. It is not mentioned in any of the current global guidelines. Therefore, stop calculating it and – for educational reasons – stop reporting it. See also what the WHO states. If any agency has [stupid] questions, hire me. ;-)

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
Activity
 Admin contact
21,835 posts in 4,569 threads, 1,554 registered users;
online 6 (0 registered, 6 guests [including 2 identified bots]).
Forum time: Friday 22:25 CET (Europe/Vienna)

No problem can stand the assault of sustained thinking.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5